2-FMA: Difference between revisions

'''2-Fluoromethamphetamine''' ('''2-FMA''') is a novel [[psychoactive class::stimulant]] substance of the [[chemical class::amphetamine]] class. 2-FMA is a member of a group known as [[substituted amphetamines]], which include compounds like [[2-FA]], [[3-FA]], and [[4-FMA]]. 2-FMA produces its stimulant effects through action at [[dopamine]] and [[norepinephrine]] receptors in the brain.  

2-FMA is commonly taken either orally or via insufflation and is reported to be highly unpleasant to vaporize. It is commonly compared to [[lisdexamfetamine]] ('''Vyvanse''') in its duration, potency and efficacy as a study or productivity aid. Despite its popularity as a research chemical study aid, little is known about the effects that may accompany its long-term use as a substitute for prescription stimulants.  

Typical effects include those of a classical stimulant such as [[stimulation]], [[focus enhancement|enhanced focus]] and [[euphoria]]. A substantial increase in adverse effects like [[increased blood pressure|high blood pressure]] and [[increased heart rate]] are often reported for dosages above the heavy dosage range.  

2-FMA is sometimes sold on the online [[research chemical]] market.<ref>Isomeric fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues ([[designer drug]]s). (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/15639609</ref><ref>Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, alpha-phthalimidopropiophenone and N-ethylcathinone (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/20074881</ref> It is strongly advised to use [[harm reduction practices]] if using this substance.

In comparison to other substituted amphetamines, 2-FMA is reported to be relatively free of side effects such as [[nausea]], [[high blood pressure]], [[anxiety]] and an uncomfortable [[offset]] ("comedown"). It is considered to be a functional stimulant for performing general productivity tasks in a manner similar to [[amphetamine]] or [[lisdexamfetamine]] (Vyvanse). However, at higher doses, it typically loses its productivity and focus-enhancing effects and begins to take on a recreational character due to the distracting euphoria that it can produce.  

*'''[[Effect::Stimulation]]''' - In terms of its effects on the physical energy levels of the user, 2-FMA is usually considered to be very energetic and stimulating in a fashion that is slightly weaker to that of [[methamphetamine]], but stronger than that of [[modafinil]], [[caffeine]], and [[methylphenidate]]. The particular style of stimulation which 2-FMA presents can be described as forced. This means that, at higher dosages, it becomes difficult or impossible to keep still as jaw clenching, involuntary bodily shakes and vibrations become present, resulting in extreme shaking of the entire body, unsteadiness of the hands, and a general loss of fine motor control.  

*'''[[Effect::Physical euphoria]]'''

*'''[[Effect::Teeth grinding]]''' - This component can be considered to be less intense when compared with that of [[MDMA]].

 

* [https://www.erowid.org/experiences/subs/exp_2Fluoromethamphetamine.shtml Erowid Experience Vaults: 2-FMA]

===Tolerance and addiction potential===

The use of compounds in the amphetamine class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., [[Paranoia|paranoia]], [[External hallucinations|hallucinations]], or [[Delusions|delusions]]).<ref>http://www.drugabuse.gov/drugs-abuse/emerging-trends</ref><ref name="amppsychosis">Shoptaw, S. J., Kao, U., & Ling, W. (2009). Treatment for amphetamine psychosis. The Cochrane Library.</ref> A review on treatment for amphetamine, [[amphetamine|dextroamphetamine]], and [[methamphetamine]] abuse-induced psychosis states that about 5–15% of users fail to recover completely.<ref name="amppsychosis" /><ref>Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (2nd ed.). New York: Oxford University Press. p. 329. ISBN 9780195030570.</ref> The same review asserts that, based upon at least one trial, [[antipsychotic]] medications effectively resolve the symptoms of acute amphetamine psychosis.<ref name="amppsychosis" />

*'''Canada''': 2-FMA would be considered Schedule I as it is an analogue of Amphetamine.<ref>Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28</ref>

*'''Germany''': 2-FMA is controlled under Anlage I BtMG (''Narcotics Act, Schedule I'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html|title=Anlage I BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 19, 2019|language=de}}</ref> as of December 13, 2014.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?start=%2F%2F*%5B%40attr_id%3D%27bgbl114s1999.pdf%27%5D|title=Zweite Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|access-date=December 19, 2019|language=de}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=§ 29 BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 19, 2019|language=de}}</ref>

*'''New Zealand''': 2-FMA is an amphetamine analogue, so is a Schedule 3 controlled substance in New Zealand.<ref>http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576</ref>

*'''United Kingdom''': 2-FMA is considered a Class A drug as a result of the amphetamine analogue clause of the Misuse of Drugs Act 1971.<ref>Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I</ref>